Bold takeaway: Rare presentations of ABPA can masquerade as TB, delaying diagnosis and risking severe airway damage.
A newly reported case expands the known range of allergic bronchopulmonary aspergillosis (ABPA) by describing an extremely uncommon manifestation: pyopneumothorax. This condition is not typically linked to ABPA and poses diagnostic challenges in regions with a high burden of tuberculosis.
The patient, a 23-year-old woman with poorly controlled asthma, presented with worsening shortness of breath, chest pain, and a large left-sided pyo-pneumothorax. Imaging showed complete obstruction of the left main bronchus by a dense mucus plug and opposite-side bronchiectasis, patterns more consistent with a chronic allergic airway process than a simple infection.
Laboratory findings reinforced the ABPA diagnosis: total serum IgE was markedly elevated (over 6,300 IU/mL), with high levels of Aspergillus fumigatus–specific IgE and IgG. Collectively, these data satisfied the modified ISHAM criteria for ABPA.
Pleural Involvement Expands ABPA’s Clinical Range
Traditionally, ABPA features allergic airway inflammation, mucus plugging, and central bronchiectasis. Pleural involvement is considered rare, with previously reported complications including pleural effusion, empyema, hydropneumothorax, and, as in this case, pyopneumothorax.
Hypothesized mechanisms include severe immune-mediated pleural inflammation, superimposed bacterial infection, and complications from long-standing fibrotic airway disease.
Therapeutic response followed standard ABPA management: systemic corticosteroids combined with itraconazole. The patient’s air leak resolved, and follow-up imaging demonstrated substantial improvement, leaving only mild pleural thickening as a residual finding.
Why Early Recognition Matters in TB-Endemic Areas
The authors emphasize that ABPA is frequently misdiagnosed as tuberculosis in low- and middle-income countries due to overlapping clinical signs and radiographic features. Such delays can allow airway destruction and pleural complications to progress. The clinical takeaway for practitioners is clear: in asthmatic patients with pleural disease, markedly elevated IgE, and mucus plugging, ABPA should be considered—even when tuberculosis remains prevalent—so that timely, appropriate treatment can prevent irreversible airway damage.
Reference
Saini JK et al. Allergic Bronchopulmonary Aspergillosis Presenting as Pyopneumothorax. Ann Afr Med. 2025; DOI: 10.4103/aam.aam45225.
Author note: This article is shared under the Creative Commons Attribution-Non Commercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/).
